JP2015501146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501146A5 JP2015501146A5 JP2014535165A JP2014535165A JP2015501146A5 JP 2015501146 A5 JP2015501146 A5 JP 2015501146A5 JP 2014535165 A JP2014535165 A JP 2014535165A JP 2014535165 A JP2014535165 A JP 2014535165A JP 2015501146 A5 JP2015501146 A5 JP 2015501146A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 344
- 239000012634 fragment Substances 0.000 claims description 174
- 239000000427 antigen Substances 0.000 claims description 113
- 102000036639 antigens Human genes 0.000 claims description 113
- 108091007433 antigens Proteins 0.000 claims description 113
- 229920001184 polypeptide Polymers 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
- 125000004122 cyclic group Chemical group 0.000 claims description 59
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 49
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 49
- 125000000539 amino acid group Chemical group 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- 241000282472 Canis lupus familiaris Species 0.000 claims description 37
- 230000001404 mediated effect Effects 0.000 claims description 33
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 28
- 241000282465 Canis Species 0.000 claims description 24
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 24
- 241000282324 Felis Species 0.000 claims description 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 22
- 241000282326 Felis catus Species 0.000 claims description 21
- 241000894007 species Species 0.000 claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 210000004897 n-terminal region Anatomy 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 208000007475 hemolytic anemia Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 44
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546865P | 2011-10-13 | 2011-10-13 | |
| US61/546,865 | 2011-10-13 | ||
| PCT/GB2012/052532 WO2013054127A1 (en) | 2011-10-13 | 2012-10-12 | Canine/feline cd20 binding epitope and compositions for binding thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015501146A JP2015501146A (ja) | 2015-01-15 |
| JP2015501146A5 true JP2015501146A5 (cg-RX-API-DMAC7.html) | 2015-12-03 |
Family
ID=47023030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535165A Pending JP2015501146A (ja) | 2011-10-13 | 2012-10-12 | イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140294819A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2766391A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015501146A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012322445B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2851758A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1201281A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013054127A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014368449C1 (en) * | 2013-12-20 | 2021-05-06 | Intervet International B.V. | Canine antibodies with modified CH2-CH3 sequences |
| AU2017219596B2 (en) | 2016-02-18 | 2019-07-04 | Elanco Us Inc. | Chimeric canine anti-CD20 antibody |
| US11673961B2 (en) * | 2018-02-20 | 2023-06-13 | Memorial Sloan Kettering Cancer Center | Anti-CD20 antibody and uses thereof |
| JP7695228B2 (ja) * | 2019-07-15 | 2025-06-18 | インターベット インターナショナル ベー． フェー． | ヒト及びイヌｃｔｌａ－４に対するイヌ化抗体 |
| AU2020336210A1 (en) * | 2019-08-29 | 2022-03-03 | Elanco Us Inc. | Anti-IL31 antibodies for veterinary use |
| JP2021059499A (ja) | 2019-10-03 | 2021-04-15 | 日本全薬工業株式会社 | イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント |
| CA3224517A1 (en) * | 2021-06-17 | 2022-12-22 | Petmedix Ltd | Anti canine cd20 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2469833C (en) * | 2001-12-21 | 2008-05-20 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| JP4263951B2 (ja) * | 2003-06-20 | 2009-05-13 | 財団法人日本生物科学研究所 | イヌ化抗体の作成方法および使用 |
| WO2006007202A2 (en) * | 2004-05-28 | 2006-01-19 | Idexx Laboratories, Inc | Canine cd20 compositions |
| CA2711882C (en) * | 2008-01-11 | 2016-07-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Improved humanized anti-human .alpha.9-integrin antibody |
| WO2010027488A2 (en) * | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| WO2011057188A1 (en) * | 2009-11-06 | 2011-05-12 | Idexx Laboratories, Inc. | Canine anti-cd20 antibodies |
-
2012
- 2012-10-12 US US14/351,392 patent/US20140294819A1/en not_active Abandoned
- 2012-10-12 JP JP2014535165A patent/JP2015501146A/ja active Pending
- 2012-10-12 EP EP12773109.9A patent/EP2766391A1/en not_active Withdrawn
- 2012-10-12 HK HK15101787.8A patent/HK1201281A1/xx unknown
- 2012-10-12 WO PCT/GB2012/052532 patent/WO2013054127A1/en not_active Ceased
- 2012-10-12 CA CA2851758A patent/CA2851758A1/en not_active Abandoned
- 2012-10-12 AU AU2012322445A patent/AU2012322445B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7589269B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2015501146A5 (cg-RX-API-DMAC7.html) | ||
| TWI756204B (zh) | 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法 | |
| KR102742528B1 (ko) | 항-bcma 중쇄-단독 항체 | |
| KR102103159B1 (ko) | 항-ｉｌ-33 항체 및 이의 용도 | |
| AU2013243644C1 (en) | Anti-HLA-B*27 antibodies and uses thereof | |
| Burnett et al. | Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability | |
| KR102729973B1 (ko) | 인플루엔자 헤마글루티닌에 대한 인간 항체 | |
| Bergeron et al. | Comparative functional characterization of canine IgG subclasses | |
| KR20220158053A (ko) | 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체 | |
| DK2475684T3 (en) | HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2 | |
| KR102073034B1 (ko) | 항cxcr3 항체 | |
| AU2025203751A1 (en) | Anti-BCMA heavy chain-only antibodies | |
| RS66170B1 (sr) | Monoklonalno antitelo protiv interleukina-31 | |
| US20230068663A1 (en) | Novel lilrb2 antibodies and uses thereof | |
| JP7008020B2 (ja) | ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体 | |
| JP2018518152A5 (cg-RX-API-DMAC7.html) | ||
| KR20150127618A (ko) | Nav1.7에 대한 사람 항체 | |
| KR20130109981A (ko) | 사람 ｇｄｆ８에 대한 항체 | |
| JP2023540444A (ja) | 治療用抗体 | |
| JP2022512904A (ja) | 抗Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ抗体およびその使用 | |
| KR20200135435A (ko) | 항-PfRH5 항체 및 이의 항원 결합 단편 | |
| Rizzi et al. | Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome | |
| Xu et al. | Expressional analysis of immunoglobulin D in cattle (Bos taurus), a large domesticated ungulate | |
| US20240423176A1 (en) | Full-length human ace2 mouse model susceptible to emerging coronaviruses |